IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
Status:
RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study was designed to reflect the safety pharmacokinetics and preliminary efficacy of MG-K10 Humanized Monoclonal Antibody Injection in adolescent patients 12-18 weeks of age with moderate to severe atopic dermatitis, administered every 2 or 4 weeks for 8 weeks